Affected by 63I-2-236 on 12/31/2023
Effective 5/4/2022
36-29-303. Duties.
- (1)
- (a) The task force shall provide evidence-based recommendations on any psychotherapy drug that the task force determines may enhance psychotherapy when treating a mental illness.
- (b) For a psychotherapy drug described in Subsection (1)(a), the task force shall provide recommendations on:
- (i) types or symptoms of mental illness for which the psychotherapy drug could be used as a treatment option;
- (ii) the appropriate administration and dosage;
- (iii) any license or credential required for an individual recommending or administering the psychotherapy drug;
- (iv) training that may be helpful or should be required for an individual to recommend or administer the psychotherapy drug;
- (v) if an additional license or credential is recommended for prescribing or administering the psychotherapy drug, the administration of the license or credential;
- (vi) the frequency at which the psychotherapy drug may be used;
- (vii) any procedures to appropriately obtain, store, and monitor the use of the psychotherapy drug;
- (viii) potential psychotherapeutic modalities with which a psychotherapy drug may be used;
- (ix) any organizations that may be able to provide a perspective on ethical considerations regarding the psychotherapy drug;
- (x) any safety requirements regarding the psychotherapy drug;
- (xi) any necessary follow up procedures that should be followed after an individual takes the psychotherapy drug;
- (xii) any procedures for data tracking;
- (xiii) any additional investigation or research needed for the psychotherapy drug;
- (xiv) any long term societal impacts on the administration of the psychotherapy drug; and
- (xv) proposed regulations the Legislature should consider if the psychotherapy drug is made legal for treating mental illness.
- (2) The task force shall provide a written report to the Health and Human Services Interim Committee before October 31, 2022.
Enacted by Chapter 141, 2022 General Session